News from our Partners
Find out the latest from our Partners and Affiliates
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete [...]
Is it MS or Something Else? updated guide is published to expedite and uncover the answer
MIDDLETON, WI., July 19, 2023 - An international consortium led by the Americas Committee for Treatment and Research in Multiple [...]
Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
Phase III OCARINA II trial met primary and secondary endpoints Ocrevus 10-minute injection has the potential to further improve the [...]
NeurologyLive® and CMSC announce Giants of Multiple Sclerosis® 2023 class of inductees
CRANBURY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased [...]
Multiple sclerosis discovery could end disease’s chronic inflammation
CHARLOTTESVILLE – Multiple sclerosis affects nearly a million Americans. Symptoms can include muscle spasms, stiffness, weakness, [...]
Congratulations to Dr. Carrie Hersh for her recent publication on DMTs
Updates and advances multiple sclerosis neurotherapuetics Moein Amin1 & Carrie M Hersh*,2 1Cleveland Clinic, Department of [...]
The launch of the ROADMAP tool on Rare Disease Day 2023
The Castleman Disease Collaborative Network (CDCN) is delighted to announce the launch of the ROADMAP drug repurposing tool. The [...]
Meghan Beier recently joined the Rowan Center for Behavioral Health
Meghan Beier recently joined the Rowan Center for Behavioral Health. Rowan is a well-established psychotherapy practice focused on [...]
Helius launches UpScript telehealth e-commerce site
PDF Version New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps NEWTOWN, Pa., Jan. 03, 2023 [...]
A new patient assistance offering from Janssen
FOR INSURED PATIENTS WHO ARE FACING ACCESS AND AFFORDABILITY CHALLENGES Janssen believes that access and affordability challenges [...]
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Janssen Pharmaceuticals U.S. transparency report
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Genentech premiers #MSVisibility 2022
Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
Sanofi’s 2022 annual pricing principles report
I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
MR epectroscopic imaging may help better diagnose, treat multiple sclerosis
Magnetic resonance spectroscopic imaging (MRSI) performed at 7.0 T (7.0-T MRSI) could visualize pathologic findings of multiple sclerosis [...]
Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
NeurologyLive® announces the inaugural Giants of Multiple Sclerosis™ Program
NeurologyLive® Announces the Inaugural Giants of Multiple Sclerosis™ Program The first annual award program will honor [...]
The Brain Under Siege by Dr. Howard Weiner
The CMSC and IOMSN are proud to announce the following: Dr. Howard L. Weiner has just written a new book on brain diseases called The [...]
Introducing Atara Biotherapeutics: the role of EBV in multiple sclerosis and the Phase II EMBOLD study
Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday - June 10, 2021 at 7:00 PM - 8:00 PM ET on an [...]
MRI in Multiple Sclerosis Guidelines Update: North America, Europe align on new recommendations
These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more [...]
Congratulations to Dr. Robert Lisak: recipient of ANA’s Distinguished Neurology Teacher Award
The CMSC Board, staff, and members would like to congratulate Dr. Robert Lisak for his selection as a recipient of the 2021 Distinguished [...]
Study on cognitive processing speed changes in RMS subjects treated with Ozanimod
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Janssen announces U.S. FDA approval of PONVORY™ (ponesimod)
Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than [...]
NeurologyLive® & the CMSC launches MS Cure Connections® Video Series
A diverse panel including an expert neurologist, a psychologist, a patient, and a care partner discuss the patient's journey with [...]
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
Please be advised of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
Mylan brings critical access to the multiple sclerosis community
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
WHO and AMA statement
"The Trump administration's official withdrawal from the World Health Organization (WHO) puts the health of our country at grave risk. As [...]
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
Multiple sclerosis patients can benefit from expanded services from MSAA
In light of the COVID-19 pandemic and its impact on the MS community, please know the Multiple Sclerosis Association of American (MSAA) has [...]
ZEPOSIA launch press release
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of [...]
Rebif® U.S. label includes pregnancy outcomes & lactation information
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]
New 6-year data for Genentech’s Ocrevus (ocrelizumab) findings
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in [...]
Coronavirus and multiple sclerosis reporting database
COViMS (COVID-19 Infections in MS & Related Diseases) is a joint effort of the Consortium of MS Centers (CMSC) and the National MS [...]
FDA approves Zeposia (Ozanimod), oral therapy for all with relapsing multiple sclerosis
The U.S. Food and Drug Administration (FDA) has approved Zeposia (ozanimod) oral capsules to treat adults with relapsing forms [...]
CMSC update on COVID-19: NMSS National Medical Advisory Committee recommendations
The Centers for Disease Control and Prevention (CDC) are following the outbreak of coronavirus (COVID-19), which causes a respiratory [...]
Multiple sclerosis and COVID-19 registry
Dear Colleagues and Clients: We know you are interested in what happens to people with MS and related diseases who develop [...]
Please read: Coronavirus and multiple sclerosis statement
The MS International Federation (also known as MSIF) has compiled information and a video (available here) which sufficiently [...]
Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
NeurologyLive™ adds CMSC to its Strategic Alliance Partnership program
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive™, a multimedia platform dedicated to providing health care professionals treating [...]
EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Genentech presents new six-year Ocrevus (Ocrelizumab) data
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]
Genentech’s Satralizumab significantly reduced relapse risk
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at [...]
Genentech presents new Ocrevus (Ocrelizumab) biomarker data
Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS [...]
Press release – Genentech to present piviotal data at ECTRIMS
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis [...]
Rutgers Health leading program to support multiple sclerosis children
Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program, the only program in the state of New [...]
Dr. Anne Cross discusses strides In multiple sclerosis research, recent award
Years ago, when many multiple sclerosis researchers believed that a type of immune cell known as a T-cell was the cause of the disease, Dr. [...]
EMD Serono’s embracing carers launches ‘Time Counts’ to raise 1M minutes of support
Rockland, MA – EMD Serono, the biopharmaceutical company of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that [...]
CMSC opens weeklong mental health program to help mentor and train multiple sclerosis specialists
The Consortium of Multiple Sclerosis Centers (CMSC), working with the Foundation of the CMSC (FCMSC) and EMD Serono, launched a [...]
Alexion’s Soliris gets new, and lucrative, rare disease indication
June 28, 2019 (This news originally appeared in PharmaPhorum Website [...]
CMSC, multiple sclerosis non-profits and Polar Products recognizes over twenty years of progress
The quality of life benefits of cooling garments for people who suffer from heat intolerance is now recognized as never before thanks to [...]
Lenox Hill Hospital multiple sclerosis support group
Encouragement and Empowerment for People With MS. Living with MS has its challenges, but you don’t have to face them alone. Lead [...]
Genentech presenting new Ocrevus (Ocrelizumab) data at AAN Meeting
Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and [...]
MSAA recognizes ten years of artwork from individuals with multiple sclerosis
CHERRY HILL, N.J., May 2, 2019 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to recognize ten years of [...]
OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis
PORTLAND, Ore. (KATU) – They're calling it a potential game-changer. Doctors at Oregon Health and Science University are part of a new [...]
Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
Novartis receives FDA approval for MAYZENT (Siponimod)
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]
Novartis announces FDA filing acceptance of Siponimod (BAF312)
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating [...]
New efficacy and safety data on multiple sclerosis portfolio to be presented
Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show [...]
Press release – Ocrevus data show early initiation reduces progression
Dear Advocates, OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in [...]
Novartis announces PARADIGMS study demonstrating benefit of Gilenya®
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents [...]
Call for test sites: using patient-reported outcomes to drive multiple sclerosis care
Researchers at Northwestern University are seeking volunteers to participate in the pilot testing of a new quality measure for [...]
Genentech announces new Ocrevus (Ocrelizumab) data for PPMS
Dear Advocates, We are pleased to announce that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European [...]
TREAT-MS
Dr. Scott Newsome and Dr. Ellen Mowry are pleased to announce the launch of their TREAT-MS trial at Hopkins. They will be activating and [...]
New Ocrevus (Ocrelizumab) data demonstrate reductions In activity & progression In RMS
We are pleased to announce that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual [...]
Imagerywork
Dr. Miriam Franco, PSY.D, MSCS, has developed a new APP that includes a separate page for Guided Imagery for MS, Improving Mood, Relieving [...]
Phase III data in the lancet show Novartis outcomes in secondary progressive multiple sclerosis
EAST HANOVER, N.J., March 22, 2018 – Novartis today announced that the full results from the Phase III EXPAND study of oral, [...]
Abbvie and Biogen pull multiple sclerosis drug Zinbryta following urgent EMA safety review
Seven of the cases were identified in Germany and one in Spain, and included encephalitis and meningoencephalitis. The pharma pair said in [...]
CVS/Aetna combo a formidable pharma rival when it comes to access
Last month's unusual consolidation of healthcare provider CVS Health with insurance company Aetna spawned a new behemoth that could pose a [...]
National Multiple Sclerosis Society endorses multiple sclerosis “NARCRMS” data registry
NEW YORK, Dec. 4, 2017 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society is proud to announce its endorsement of [...]
Mayo Clinic develops test to distinguish other demyelinating diseases from multiple sclerosis
The Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis [...]
International Journal of Multiple Sclerosis Care wins 2017 APEX Award
The International Journal of MS Care has received an Award of Excellence in the APEX 2017 Awards for Publication Excellence [...]
OMRF multiple sclerosis center wins top multiple sclerosis research award
OKLAHOMA CITY — The Oklahoma Medical Research Foundation's Multiple Sclerosis Center of Excellence won the Labe Scheinberg Award at the [...]
Research sheds light on who’s multiple sclerosis could worsen
A preliminary study by senior author Bianca Weinstock-Guttman, MD, has heightened researchers’ understanding about which adults with [...]
Bayer receives FDA approval of myBETAapp™ and BETACONNECT Navigator™
WHIPPANY, N.J., May 30, 2017 – Bayer today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental [...]
CMSC 2017 Annual Meeting – Celgene’s investigational therapy Ozanimod safe, effective in treating RMS
Long-term treatment for up to 12o weeks, with the investigational drug Ozanimod (RPC-1063), found to be effective and safe in patients [...]
CMSC 2017 Annual Meeting – Rituxan-treated multiple sclerosis patients three times more likely to have improved brain scans
Multiple sclerosis patients who start Rituxan (rituximab) treatment are three times more likely to have unchanged or improved brain-scan [...]
CMSC 2017 Annual Meeting – review suggests certain multiple sclerosis patient groups may discontinue DMTs
Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after [...]
CMSC 2017 Annual Meeting – Tysabri improves mental outlook for patients with secondary progressive MS
Long-term therapy with Tysabri (natalizumab) significantly improved the mental state of people with secondary progressive multiple [...]
CMSC 2017 Annual Meeting – multiple sclerosis patients should contribute to outcome measure development, study argues
Patients must help develop new outcome measures of multiple sclerosis (MS), since they and healthcare providers may have differing [...]
CMSC 2017 Annual Meeting – single session of ball-throwing exercise improves balance control in multiple sclerosis
Patients with relapsing-remitting multiple sclerosis (RRMS) regain part of their balance control after a single training session of [...]
CMSC 2017 Annual Meeting – Genentech starts site to connect multiple sclerosis patients and caregivers with resources
Genentech has rolled out a website to connect multiple sclerosis (MS) patients and caregivers with resources that can help [...]
CMSC 2017 Annual Meeting – all about teamwork in multiple sclerosis
NEW ORLEANS — The Consortium of Multiple Sclerosis Centers (CMSC) annual meetings always aim to offer a multidisciplinary educational [...]
The hidden costs of multiple sclerosis
MS is sneaky. It is expert at evading detection and diagnosis, and often brings a host of invisible symptoms that may come and go at [...]
David Sackett trial of the year awarded to the Oratorio Study
At the ongoing Annual Meeting of the Society for Clinical Trials that is being jointly held with the International Clinical Trials [...]
CMSC 2017 Annual Meeting – experts to focus on multiple sclerosis patient care at CMSC Annual Meeting in New Orleans
The 31st Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) will take place May 24-27 at the Ernest N. Morial [...]
Biogen Idec to present new two-year data from the PLEGRIDY phase 3 advance study
Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 Advance Study at AAN Annual [...]
Ari Waisman receives most prestigious European prize for multiple sclerosis research
The Sobek Foundation honors Professor Ari Waisman for his groundbreaking achievements in research into multiple sclerosis (MS). His [...]
United Spinal Association offering range of materials at exhibit booth at CMSC 2016 Annual Meeting
The United Spinal Association, a nonprofit focused on improving the quality of life for people with spinal cord injuries and disorders [...]
Multiple sclerosis rehabilitation specialist, Susan Bennett, receives CMSC Lifetime Achievement Award
The Consortium of Multiple Sclerosis Centers (CMSC) has awarded Susan E. Bennett one of its highest honors, the Lifetime Achievement [...]
ICER draft report evaluating therapies for RRMS now open for public comment
The Institute of Clinical and Economic Review (ICER) released the early draft of a paper intended to inform a future report evaluating [...]
CMSC 2016 Annual Meeting – Clay Walker’s concert at the CMSC 30th anniversary celebration
Clay Walker is a very well know name and face, not only because of his music career but also for being a very eager advocate for multiple [...]
How does menopause affect women with multiple sclerosis?
Although menopause occurs in every woman who lives long enough, very little research has been done on its effects on women with multiple [...]
CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with Mark Freedman
This year, Multiple Sclerosis News Today will offer expanded coverage of the 2016 Annual Meeting of the Consortium of Multiple Sclerosis [...]
CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with Summer Kernan
In an MS News Today exclusive interview with June Halper, the CEO of the Consortium of Multiple Sclerosis Centers (CMSC), Halper saw [...]
Nine CMSC 2016 Annual Meeting exclusive interviews you can’t miss
This year, Multiple Sclerosis News Today offered expanded coverage of the 2016 Annual Meeting of the Consortium of Multiple Sclerosis [...]
CMSC 2016 Annual Meeting – Fingolimod (Gilenya) offers consistent health benefits in RRMS patients
Researchers at the Swedish Neuroscience Institute in Washington and Novartis Pharma revealed that Gilenya (fingolimod) induced a [...]
CMSC 2016 Annual Meeting – multiple sclerosis patients, physical therapists have distinct decision-making processes
Understanding and combining decision-making processes of both patients with multiple sclerosis (MS) and physical therapists to improve [...]
CMSC 2016 Annual Meeting – multiple sclerosis duration and disability level variously impacts arm function
Most research in multiple sclerosis (MS) has focused on the impact of the disease on the lower extremities. To balance this, researchers [...]
CMSC 2016 Annual Meeting – multiple sclerosis and yoga: author and instructor says ancient discipline can help patients
Mindy Eisenberg is the author of the book “Adaptive Yoga Moves Any Body” and Multiple Sclerosis News Today had the chance to hear [...]
CMSC 2016 Annual Meeting – Ocrevus (Ocrelizumab) in PPMS prevented disability progression
Data recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting showed that Roche/Genentech’s [...]
CMSC 2016 Annual Meeting – medical affairs vice president at EMD Serono discusses multiple sclerosis drug rebif, Multiple Sclerosis LifeLines
EMD Serono, the U.S. and Canadian subsidiary and biopharmaceutical business of Merck KGaA, focuses exclusively on specialty care. With [...]
CMSC congratulates Kessler Foundation for this prestigious recognition
We are extremely pleased to tell you that Kessler Foundation has been ranked #5 on a list of the “50 Best Workplaces for Recent College [...]
Dr. Ellen Mowry, in Interview, talks of clinical studies for Vitamin D & multiple sclerosis
With an interest multiple sclerosis (MS) before even starting college, Dr. Ellen Mowry has spent her entire research career investigating [...]
High glutamate levels in brain seen to drive multiple sclerosis progression
Patients with multiple sclerosis (MS) have increased levels of the neurotransmitter glutamate in their brains, lowering the levels of [...]
New data from three Phase III studies of the medicine OCREVUS™ (ocrelizumab)
GENENTECH TO PRESENT NEW DATA AT AAN SHOWING SUPERIOR EFFICACY OF NVESTIGATIONAL MEDICINE OCRELIZUMAB VERSUS COMPARATORS ON DISEASE [...]
Francois Bethoux, MD, named medical director of the Arts & Medicine Institute
Iva Fattorini, MD, has stepped down from her role as Global Chair of the Arts & Medicine Institute, effective Jan. 1. Cleveland Clinic [...]
National Multiple Sclerosis Society honors physician
DERBY — Joseph Guarnaccia, M.D., clinical director of the Multiple Sclerosis Treatment Center at Griffin Hospital, was recently inducted [...]
MedDay misses endpoint in phase III multiple sclerosis vision loss trial
A Phase III trial of MedDay's multiple sclerosis drug has missed its primary endpoint. The drug, which made headlines in April when it [...]
Biogen reports top-line results from phase 3 study evaluating Natalizumab in SPMS
Wednesday, October 21, 2015 7:31 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Phase 3 ASCEND study investigating natalizumab in the [...]
EMD Serono announces publication of PRISMS-15 year follow-up study using Rebif in RRMS
Rockland, Massachusetts, October 12, 2015 – EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today [...]
Treatment effects maintained over 5 years in patients with RRMS who received Lemtrada
Thursday, October 8, 2015 1:00 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, aSanofi company, today announced positive new [...]
Genentech’s Ocrelizumab show positive pivotal study results in both RRMS and PPMS
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive [...]
EMD Serono announces recipients of the third annual €1 million grant for multiple sclerosis innovation
EMD Serono Announces Recipients of the Third Annual €1 Million Grant for Multiple Sclerosis Innovation Four research grants awarded [...]
New analysis suggests Aubagio slows brain atrophy in people with Relapsing MS
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Additional MRI data on [...]
Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis [...]
Genzyme introduces “vs.MS”, a global initiative
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed [...]
Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large [...]
Bayer receives FDA approval for BETACONNECT
Intended for U.S. Media Only Whippany, N.J., September 25, 2015 – Bayer HealthCare announced today that the U.S. Food and Drug [...]
Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications Novartis [...]
EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Multiple Sclerosis Coalition applauds passage of 21st Century Cures Act
Multiple Sclerosis Coalition Applauds Passage of 21st Century Cures Act Inclusion of data-gathering provision is vital to future MS [...]
Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Multiple Sclerosis Coalition announces new board President
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]
Novartis statement on reported case of PML
Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoencephalopathy [...]
FDA accepts biologics license application for ZINBRYTA for treatment of multiple sclerosis
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Acceptance Follows [...]
Mallinckrodt research fellowship award program announcement
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Research Fellowship [...]
FDA accepts filing of BETACONNECT for RRMS patients taking BETASERON
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b) Offers [...]
International survey identifies opportunities for improving multiple sclerosis treatment satisfaction
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction Many Factors Influence Patient [...]
TECFIDERA Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients TECFIDERA Provides Robust and [...]
EMA validates marketing authorization application for ZINBRYTA for treatment of multiple sclerosis
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of [...]
Teva Neuroscience & Access Health team up for special multiple sclerosis awareness show: thursday, 3/5
Teva Neuroscience & Access Health Team Up for Special MS Awareness Show: Thursday, March 5 As Multiple Sclerosis Awareness Week [...]
Acorda announces data from first clinical trial of remyelinating antibody in multiple sclerosis
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis Phase 1 trial [...]
First multiple sclerosis patients in the U.S. receive Genzyme’s Lemtrada following FDA approval
First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval – Lemtrada now available in the U.S. two weeks post [...]
Genzyme’s Lemtrada approved by the FDA
Genzyme’s Lemtrada Approved by the FDA - Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows [...]
Genzyme announces enrollment of first patient in phase II Vatelizumab trial in RRMS
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Tuesday, November [...]
Study on abnormal MRIs and the risk of developing multiple sclerosis featured in the IJMSC
Study on Abnormal MRIs and the Risk of Developing MS Featured in the International Journal of MS Care (Hackensack, NJ, October [...]
Optimizing multiple sclerosis management – new CME/CE courses for healthcare professionals
Optimizing Multiple Sclerosis Management: New CME/CE Regional Courses for Healthcare Professionals (Hackensack, NJ, October 2014)— The [...]
Results from two phase III studies added to U.S. label of Genzyme’s Aubagio
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio Once-daily Aubagio is the only oral treatment to [...]
Employment in Multiple Sclerosis (MS) study
Employment in Multiple Sclerosis (MS) Study Multiple sclerosis (MS), the leading cause of neurological disability among young and [...]
Novartis teams up with multiple sclerosis advocate David Osmond to launch Our Voice in Song
Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™ [...]
At four years, treatment effect maintained in patients who received Lemtrada in studies
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies - In [...]
New international survey finds multiple sclerosis patients and neurologists view communication positively
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS [...]
IJMSC features article on the Multiple Sclerosis Self-Management Scale
International Journal of MS Care Features Article on the Multiple Sclerosis Self-Management Scale (Hackensack, NJ, August 2014)—The [...]
AIMS presents the latest on multiple sclerosis treatments
AIMS Presents the Latest on Multiple Sclerosis Treatments Educational Programs for Healthcare Professionals Includes Live Events & [...]
Biogen Idec’s PLEGRIDY approved in the US for the treatment of multiple sclerosis
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Friday, August 15, 2014 [...]
PLEGRIDY (Peginterferon beta-1a) approved in the EU for the treatment of multiple sclerosis
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Wednesday, July 23, 2014 [...]
Teva files citizen petition with the US FDA regarding the complexity of COPAXONE
Teva files Citizen Petition with the U.S. Food and Drug Administration (FDA) regarding the Complexity of COPAXONE® (Glatiramer Acetate) [...]
Genzyme’s Lemtrada approved in Argentina for treatment of multiple sclerosis
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis Monday, June 30, 2014 8:00 am EDT CAMBRIDGE, [...]
Biogen Idec and AbbVie Announce Results from Phase 3 Study Investigating Daclizumab
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple [...]
Genzyme’s Lemtrada resubmission accepted for review by FDA
Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 - Cambridge, Mass. - May 30, 2014 - [...]
Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at congresses
Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses Friday, May 30, 2014 [...]
Biogen Idec announces official partnership with Sailing Sclerosis’ “Oceans of Hope”
Biogen Idec Announces Official Partnership with Sailing Sclerosis Oceans of Hope to Globally Change Perceptions of MS Wednesday, May [...]
EMD Serono data at CMSC & ACTRIMS Annual Meeting reinforces proven efficacy of rebif
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued [...]
Acorda Therapeutics to showcase online multiple sclerosis resources at 2014 CMSC/ACTRIMS meeting
Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting 05/27/2014 The award-winning [...]
Genzyme recognizes sixth annual World MS Day
Genzyme Recognizes Sixth Annual World MS Day - Company Supporting Wide Range of Programs to Help Improve the Lives of People Living with [...]
CHMP adopts positive opinion for PLEGRIDY as a treatment for multiple sclerosis in the EU
CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union Friday, [...]
Teva announces COPAXONE recognized as “Brand of the Year” by Pharm Exec Magazine
Teva announces COPAXONE® recognized as Brand of the Year by Pharmaceutical Executive Magazine JERUSALEM--(BUSINESS WIRE)--May 8, [...]
New TYSABRI analysis shows improved walking speed in significant number of multiple sclerosis patients
New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients Thursday, May 1, 2014 [...]
New data reinforce efficacy of TECFIDERA in multiple sclerosis patients with high disease activity
New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity Wednesday, April 30, 2014 7:30 [...]
A farewell tribute to Mike Robinson – President, National Multiple Sclerosis Society of Zimbabwe
A Farewell Tribute to Mike Robinson – President, Multiple Sclerosis Society of Zimbabwe POET AND SALUTATION DEDICATION: MR. [...]
Slowing of brain atrophy sustained at three years in patients treated with Lemtrada
Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s [...]
Genzyme announces multi-year multiple sclerosis research collaboration with academic medical center
Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center Wednesday, April 30, 2014 [...]
Dr. T.J. ‘Jock’ Murray is a 2014 inductee to the Canadian Medical Hall of Fame
2014 INDUCTEE TO THE CANADIAN MEDICAL HALL OF FAME Dr. T.J. 'Jock' Murray, OC ONS Category for Induction: Builder Education: MD, [...]
Teva announces supreme court denial of request for interim relief to stay
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for Copaxone® Patent Due to the [...]
Biogen Idec to present new clinical data at AAN Annual Meeting
Biogen Idec to Present New Clinical Data from its Robust Neurology Portfolio at AAN Annual Meeting Monday, April 14, 2014 7:30 am [...]
New continuing education program helps distinguish between primary care needs & multiple sclerosis symptoms
New Continuing Education Program Helps Practitioners Distinguish Between Primary Care Needs & Multiple Sclerosis Symptoms Top Health [...]
